Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$4.11 USD
+0.10 (2.49%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $4.03 -0.08 (-1.95%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
APRE 4.11 +0.10(2.49%)
Will APRE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for APRE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APRE
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
APRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies
Other News for APRE
Buy Rating on Aprea Therapeutics: Outshining Competitors with Selective and Potent WEE1 Inhibitor APR-1051
Buy Rating Affirmed for Aprea Therapeutics on APR-1051’s Promising Safety and Efficacy Profile
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
Aprea Therapeutics’ APR-1051: Poised for Leadership in WEE1 Inhibition with Promising Clinical and Market Potential
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Gossamer Bio (GOSS) and Aprea Therapeutics (APRE)